Gilead can’t escape patent trial over hep c drugs

By Scott Graham, From The Recorder It looks as if Gilead Sciences will have to roll the dice on trial next month if it wants to protect the patent rights to its blockbuster hepatitis C treatment. It wouldn’t be the…